Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study
European Journal of Cancer2018Vol. 96, pp. 82–90
Citations Over TimeTop 10% of 2018 papers
Naiba Nabieva, Tanja Fehm, Lothar Häberle, J. De Waal, Mahdi Rezai, B. Baier, Gerold Baake, Hans‐Christian Kolberg, Martin Guggenberger, Mathias Warm, Nadia Harbeck, Rachel Wuerstlein, Jörg-Uwe Deuker, Peter Dall, Barbara Richter, Grischa Wachsmann, Cosima Brucker, J. W. Siebers, Miloš Popović, Thorsten Kühn, Christopher Wolf, Hans‐Walter Vollert, G. P. Breitbach, Wolfgang Janni, R. Landthaler, A. Kohls, Daniela Rezek, Thomas Noesselt, G. Fischer, Stefan Henschen, Thomas Praetz, Volker Heyl, Tarah Kuhn, Thomas F. Krauss, Christoph Thomssen, Andre Hohn, Hans Tesch, Christoph Mundhenke, Alexander Hein, Carolin C. Hack, Katja Schmidt, Erik Belleville, Sara Y. Brucker, Sherko Kümmel, Matthias W. Beckmann, D. Wallwiener, Peyman Hadji, Peter A. Fasching
Related Papers
- → Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole(2004)32 cited
- → A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women(2008)29 cited
- → Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer(2010)7 cited
- → An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole(2004)8 cited